“April 2017 : Intensification of the Company’s international development with the appointment of a new CEO : Mrs Nawal Ouzren”
“Sensorion aims to become a major player in the development of inner ear disease treatments of and thus fulfill unmet medical needs”
"Our mission is to develop innovative and targeted treatments for inner ear diseases with vertigo, tinnitus, hearing loss"
" Sensorion, has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential"
sensorion video simple


Key Opinion Leader Event :
Novel approaches to treating
Acute Unilateral Vestibulopathiy (AUV)

London, November 29, 2016

Sensorion is a biopharmaceutical company committed to finding targeted and innovative treatments for inner ear disease.

Dysfunction or complete loss of function of the vestibular or cochlear system can induce vertigo, imbalance, tinnitus, hearing loss and leads to transient or permanent disability. Unfortunately there are no truly effective, approved and well tolerated treatments available for patients suffering from inner ear pathologies.

Founded in 2009, Sensorion is a French biopharmaceutical company dedicated to the development of targeted and innovative therapies to treat such disorders and fill the currently unmet medical needs.

The company is located in Montpellier (France). At the interface between academic research and industrial development, we adopt a multidisciplinary approach in collaboration with various partners in the ENT field (researchers, clinicians…) to develop new drugs.